Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDarinaparsin: a novel organic arsenical with promising anticancer activity
Expert Opinion on Investigational Drugs, 09/30/09
Mann KK et al. – Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, have been used clinically, none have shown significant activity in malignancies outside of acute promyelocytic leukemia. Darinaparsin has significant activity in a broad spectrum of hematologic and solid tumors in preclinical models.
Related Articles
Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients
Evidence-based Complementary and Alternative Medicine, 11/20/09
Relevance Score: 88%
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
British Journal of Haematology, 11/20/09
Relevance Score: 88%
Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid
Journal of Pharmacy and Pharmacology, 10/15/09
Relevance Score: 87%
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
European Journal of Internal Medicine, 11/06/09
Relevance Score: 79%
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
Cancer, 10/20/09
Relevance Score: 68%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
New agents for AML and MDS
Best Practice & Research: Clinical Haematology , 12/08/09
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/08/09
Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study
Current Medical Research and Opinion, 12/08/09
Sponsor
Article Search
Sponsor